Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Biol Trace Elem Res ; 197(2): 464-474, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31858401

RESUMEN

The effects of prepartum dietary supplementation with selenium yeast on low abundant plasma proteins in postpartum dairy cows are not known. In this study, 24 healthy parturient dairy cows were divided into two groups (group C, a control group, and group T, a selenium treatment group). Low abundance proteins were extracted from plasma samples of calving cows, and 542 proteins were identified by isobaric tags for relative and absolute quantitation (iTRAQ) proteomic analysis. Dietary supplementation with selenium yeast caused differential abundance of 48 proteins with a fold change of more than 1.2 or less than 0.83 (p < 0.05); 14 proteins were upregulated and 34 were downregulated. The top five gene ontology (GO) enrichment terms for the differentially expressed proteins were protein homotetramerization (or tetramerization), defense response to bacteria or fungus, acute-phase reactions, nucleotide catabolic process, and positive regulation of lipid metabolic process. All proteins involved in acute-phase reactions were downregulated, indicating that selenium ameliorates systemic inflammation. The vast majority of proteins involved in the defense response to microorganisms were downregulated, thereby affecting innate immunity. The decreased abundance of apolipoprotein A-I and apolipoprotein C-II, critical proteins for positive regulation of lipid metabolism, indicated that selenium may optimize lipid metabolism. The iTRAQ results showed that prenatal supplementation with yeast selenium can relieve systemic inflammation after parturition. Moreover, selenium may reduce the effects of metabolic diseases, which can improve glyconeogenesis and prevent ketosis and fatty liver.


Asunto(s)
Selenio , Animales , Bovinos , Femenino , Humanos , Lactancia , Leche , Parto , Periodo Posparto , Embarazo , Proteómica , Saccharomyces cerevisiae , Selenio/farmacología
2.
J Diabetes Investig ; 9(6): 1354-1359, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29542249

RESUMEN

AIMS/INTRODUCTION: To explore the relationship between plasma iron levels and gestational diabetes mellitus, as well as its impact on macrosomia. MATERIALS AND METHODS: We retrospectively compared ferritin level and other characteristics between pregnant women with gestational diabetes mellitus (GDM) and pregnant women without GDM. The correlation between the levels of plasma ferritin, glucose and hemoglobin was explored. Meanwhile, we assessed the risk factors of macrosomia. Furthermore, we explored the relationship between ferritin level and the incidence of macrosomia. RESULTS: A total of 793 pregnant women were enrolled in the present study, of which 92 pregnant women had GDM and 701 pregnant women were healthy. Meanwhile, 51 pregnant women gave birth to infants with macrosomia and another 742 women had normal infants. Compared with non-GDM women, pregnant women with GDM were older, with higher pre-pregnancy body mass index, plasma ferritin, fasting plasma glucose, 1-h postprandial glucose, 2-h plasma glucose and hemoglobin. In addition, our results showed a significant positive correlation between the levels of ferritin and fasting plasma glucose when ferritin levels were >70 ng/mL. Our results also showed that pre-pregnancy overweight or obesity, a high concentration of ferritin, as well as abnormal levels of fasting plasma glucose, 1-h plasma glucose and 2 h plasma glucose were risk factors for macrosomia. Furthermore, as the level of ferritin increased, so did the incidence of macrosomia. CONCLUSIONS: The current study provides evidence that pregnant women with high levels of ferritin might be prone to GDM. In addition, a high level of ferritin might be an independent risk factor for macrosomia. Therefore, the negative effect of iron supplementation in non-anemic pregnant women might be noteworthy.


Asunto(s)
Ferritinas/sangre , Macrosomía Fetal/sangre , Adulto , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Embarazo , Estudios Retrospectivos , Factores de Riesgo
3.
Sci Rep ; 6: 26924, 2016 05 27.
Artículo en Inglés | MEDLINE | ID: mdl-27229740

RESUMEN

Panax ginseng (GS) and Veratrum nigrum (VN) are representative of incompatible pairs in "eighteen antagonistic medicaments" that have been recorded in the Chinese medicinal literature for over 2,000 years. However, evidence linking interference effects with combination use is scare. Based on the estrogen-like effect of GS described in our previous studies, we undertake a characterization of the interaction on estrogenic activity of GS and VN using in vivo models of immature and ovariectomized (OVX) mice and in vitro studies with MCF-7 cells for further mechanism. VN decreased the estrogenic efficacy of GS on promoting the development of the uterus and vagina in immature mice, and reversing the atrophy of reproductive tissues in OVX mice. VN interfered with the estrogenic efficacy of GS by decreasing the increase of the serum estradiol and the up-regulation of ERα and ERß expressions by treatment with GS. And VN antagonized the estrogenic efficacy of GS on promoting the viability of MCF-7 cells and up-regulation of protein and gene expressions of ERs. In conclusion, this study provided evidence that GS and VN decreased effects on estrogenic activity, which might be related to regulation of estrogen secretion and ERs.


Asunto(s)
Estradiol/sangre , Receptor alfa de Estrógeno/genética , Receptor beta de Estrógeno/genética , Panax/química , Extractos Vegetales/farmacología , Veratrum/química , Animales , Antagonismo de Drogas , Medicamentos Herbarios Chinos , Receptor alfa de Estrógeno/metabolismo , Receptor beta de Estrógeno/metabolismo , Femenino , Hormona Folículo Estimulante/sangre , Hormona Folículo Estimulante/genética , Regulación de la Expresión Génica , Humanos , Hormona Luteinizante/sangre , Hormona Luteinizante/genética , Células MCF-7 , Medicina Tradicional China , Ratones , Ovariectomía , Maduración Sexual/fisiología , Útero/efectos de los fármacos , Útero/crecimiento & desarrollo , Útero/metabolismo , Vagina/efectos de los fármacos , Vagina/crecimiento & desarrollo , Vagina/metabolismo
4.
Sci Rep ; 5: 17436, 2015 Dec 08.
Artículo en Inglés | MEDLINE | ID: mdl-26644197

RESUMEN

The Chinese herbal preparation QiBaoMeiRan formula (QBMR) displayed estrogenic effects in ovariectomized rats after long-term administration in a previous study. The uterus and vagina are negatively influenced by estrogens in hormone therapy. While QBMR is known to be a phytoestrogen, its estrogenic effects and safety on reproductive tissues after short-term administration and its mechanism via estrogen receptor (ER) pathway haven't been studied. Here, we characterized its estrogenic effects using immature mice together with in vitro studies for further molecular characterization. Immature mice were treated with QBMR at doses of 1.125, 2.25, and 4.5 g/kg for 7 days. 1.125 and 2.25 g/kg QBMR promoted the growth and development of uterus and vagina, and upregulated ERα and ERß expression in reproductive tissues. QBMR had a stimulatory effect on proliferating cell nuclear antigen in vagina but not in uterus, and was without any influence on ki-67 antigen in uterus and vagina. QBMR significantly induced luciferase expression from the ERα/ß-estrogen response element (ERE) luciferase reporter and upregulated ERα and ERß expressions in MCF-7 cells, which were significantly inhibited by estrogen antagonist ICI182,780. This study demonstrated QBMR exerts estrogenic effects on reproductive tissues without side effects and through ER-ERE-dependent pathway.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Reproducción/efectos de los fármacos , Animales , Biomarcadores , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Moduladores de los Receptores de Estrógeno/farmacología , Estrógenos/sangre , Estrógenos/metabolismo , Femenino , Hormona Folículo Estimulante/sangre , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Hormona Luteinizante/sangre , Ratones , Membrana Mucosa/citología , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/metabolismo , Antígeno Nuclear de Célula en Proliferación/genética , Antígeno Nuclear de Célula en Proliferación/metabolismo , Receptores de Estrógenos/genética , Receptores de Estrógenos/metabolismo , Reproducción/genética , Útero/efectos de los fármacos , Útero/metabolismo , Vagina/efectos de los fármacos , Vagina/metabolismo
5.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 34(8): 922-5, 2014 Aug.
Artículo en Chino | MEDLINE | ID: mdl-25223173

RESUMEN

OBJECTIVE: To observe the therapeutic efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined Wenshen Xiaozheng Decoction (WXD) in auxiliary treating endometriosis after laparoscopy. METHODS: One hundred and thirty-four endometriosis patients with confirmative pathological diagnosis were assigned to three groups depending on whether they would receive adjuvant therapy or Chinese medicine treatment, i.e., the control group, the observation 1 group, and the observation 2 group. The 22 patients in the control group received no adjuvant therapy after laparoscopy. The 42 patients in the observation 1 group were treated with GnRHa 3.6 mg by subcutaneous injection starting from the 1st day to the 5th day of menstruation, once per 28 days. The 70 patients in the observation 2 group were treated with GnRHa 3.6 mg by subcutaneous injection in combination with WXD starting from the 1st day to the 5th day of menstruation, once per 28 days. They also took WXD for 7 doses, one cycle per every 28 days. The treatment lasted for three to six months. Serum levels of estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and cancer antigen 125 (CA125), as well as clinical efficacy, and adverse drug reactions were observed before and after treatment. RESULTS: There was statistical difference in serum levels of E2, FSH, or LH between the control group and the observation 1 and 2 groups (P < 0.05). There was no statistical difference in serum levels of E2, FSH, or LH between the observation 1 group and the observation 2 group (P > 0.05). There was statistical difference in the clinical efficiency among the 3 groups (P < 0.05). There was statistical difference in the pre-post difference of CA125 levels among the three groups (P < 0.01). Compared with the control group, there was no statistical difference in the pre-post difference of CA125 levels between the observation 1 group and the observation 2 group (P > 0.05). No obvious adverse reaction occurred during the treatment. CONCLUSIONS: GnRHa combined WXD showed confirmative clinical efficacy in treating endometriosis after laparoscopy. It also could lower serum levels of E2, FSH, and LH levels. So it was an ideal solution for treatment of endometriosis.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Endometriosis/tratamiento farmacológico , Hormona Liberadora de Gonadotropina/uso terapéutico , Adulto , Endometriosis/cirugía , Femenino , Humanos , Laparoscopía , Resultado del Tratamiento
6.
Chin J Integr Med ; 20(8): 600-9, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25087604

RESUMEN

OBJECTIVE: To investigate the effect of Ermiao Recipe (, EMR) with medicinal guide Angelicae Pubescentis Radix (APR) on the homing of bone marrow stem cells (BMSCs) to focal zone in osteoarthritis (OA) rats. METHODS: Forty-eight Sprague-Dawley rats were randomly assigned to the sham-operated, model, EMR, and EMR plus APR groups (12 rats in each group). The OA rat model was induced by anterior cruciate ligament transection and medial meniscus resection. All rats were injected with recombinant human granulocyte colonystimulating factor [rhG-CSF, 30 µg/(kg·d) for continuous 7 days], and rats in the EMR and EMR plus APR groups were treated with EMR or EMR plus APR at 1.6 or 1.9 g/(kg·d) for 3 or 6 weeks, respectively. Cartilage histopathologic changes were observed by hematoxylin and eosin staining. Chondrocytes apoptosis and cartilage matrix components were tested by transferase-mediated deoxyuridine triphosphate-biotin nick end labeling assay and special staining. Interleukin-1ß (IL-1 ß), tumor necrosis factor α (TNF-α), bone morphogenetic protein 2 (BMP-2), and transforming growth factor beta-1 (TGF-ß1) in serum were detected by enzyme-linked immunosorbent assay or radioimmunoassay assay. Matrix metalloproteinase (MMP)-13, tissue inhibitors of metalloproteinase (TIMP)-1, bromodeoxyuridine (BrdU), cluster of differentiation 34 (CD34), and stromal cell derived factor 1 (SDF-1) were measured by immunohistochemistry assay. RESULTS: EMR and EMR plus APR significantly inhibited articular cartilage damage and synovium inflammation in OA rats at 3 or 6 weeks of treatment, the most obvious changes in these parameters were found in the EMR plus APR group. At 6 weeks, compared with EMR treatment, EMR plus APR remarkably inhibited chondrocytes apoptosis and the release of IL-1ß and TNF-α, obviously decreased MMP-13 expression, and significantly increased expressions of proteoglycan, collagen, type II collagen and TIMP-1, serum levels of BMP-2 and TGF-ß1 as well as expressions of BrdU, CD34 and SDF-1 in cartilage articular (P<0.01 or P<0.05). CONCLUSION: The medicinal guide APR improved the therapeutic effects of EMR on OA rats by promoting directional homing of BMSCs to focal zone.


Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Cartílago Articular/patología , Medicamentos Herbarios Chinos/uso terapéutico , Osteoartritis/tratamiento farmacológico , Angelica , Animales , Apoptosis/efectos de los fármacos , Proteína Morfogenética Ósea 2/sangre , Bromodesoxiuridina/metabolismo , Cartílago Articular/efectos de los fármacos , Cartílago Articular/enzimología , Quimiocina CXCL12/metabolismo , Condrocitos/efectos de los fármacos , Condrocitos/patología , Medicamentos Herbarios Chinos/farmacología , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/farmacología , Humanos , Interleucina-1beta/sangre , Articulación de la Rodilla/efectos de los fármacos , Articulación de la Rodilla/patología , Masculino , Metaloproteinasa 13 de la Matriz/metabolismo , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/sangre , Osteoartritis/sangre , Osteoartritis/patología , Ratas Sprague-Dawley , Membrana Sinovial/patología , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Factor de Crecimiento Transformador beta1/sangre , Factor de Necrosis Tumoral alfa/sangre
7.
Int J Mol Sci ; 15(5): 7827-40, 2014 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-24806341

RESUMEN

Ginseng is a popular herb for alleviating menopausal symptoms; however, no conclusive scientific data has shown ginseng as being efficient in such therapies. The present study was designed to evaluate the estrogenic efficacy of ginseng on reproductive target tissues of ovariectomized (OVX) mice. The OVX mice were treated with ginseng at doses of 12.0, 18.0 and 24.0 g/kg per day for four weeks. Ginseng treatments restored the estrus cycle and demonstrated significant estrogenic activity, as indicated by the reversal of the atrophy of the uterus and vagina, upregulation of estrogen receptor (ER) α and ER ß expression at the protein and mRNA level in the reproductive tissues, where ER α upregulation was stronger than that of ER ß. Meanwhile, treatment with ginseng significantly increased adrenal gland weight and serum estradiol and clearly decreased follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in circulation. Notably, the largest changes in these parameters were found at the highest dose of 24.0 g/kg. Moreover, ginseng at 18.0 g/kg resulted in the greatest decrease in weight gain caused by ovariectomy. The data suggest that ginseng estrogenic responses show tissue variation that reflects different affinities of ERs for ginseng components. This study demonstrates that ginseng activity is mediated through estrogenic components and provides further evidence for ginseng treatment of postmenopausal symptoms.


Asunto(s)
Estrógenos/uso terapéutico , Ovariectomía , Panax , Preparaciones de Plantas/uso terapéutico , Útero/efectos de los fármacos , Vagina/efectos de los fármacos , Animales , Estradiol/sangre , Estrógenos/química , Femenino , Hormona Luteinizante/sangre , Ratones , Tamaño de los Órganos/efectos de los fármacos , Ovario/cirugía , Panax/química , Fitoterapia , Preparaciones de Plantas/química , Receptores de Estrógenos/análisis , Receptores de Estrógenos/genética , Receptores de Estrógenos/metabolismo , Regulación hacia Arriba/efectos de los fármacos , Útero/patología , Vagina/patología
8.
Rejuvenation Res ; 17(4): 372-81, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24773352

RESUMEN

Traditional Chinese medicines (TCM) contain multi-interactive compounds that have been used for treatment of peri-menopausal syndrome and have become a new phytoestrogens resource. The QiBaoMeiRan formula (QBMR), including Polygoni multiflori radix, Angelicae sinensis radix, Achyranthis bidentatae radix, semen Cuscutae, fructus Lycii, Poria, and fructus Psoraleae, has been used clinically for treating osteoporosis in post-menopausal women by virtue of its kidney-invigorating function. However, no evidence base links QBMR to estrogen replacement therapy. In this study, we undertook a characterization of estrogenic activity of QBMR using ovariectomized (OVX) rats. OVX rats were treated with QBMR at doses of 0.875, 1.75, and 3.5 grams/kg per day for 8 weeks. QBMR treatments demonstrated significant estrogenic activity, as indicated by vaginal cornification, reversal of atrophy of uterus, vagina, and mammary gland, and up-regulation of estrogen receptor α (ERα) and estrogen receptor ß (ERß) expression in the reproductive target tissues, where ERß up-regulation was stronger than that of ERα. Meanwhile, treatment with QBMR significantly increased adrenal weight and serum estradiol levels and tended to decrease serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in a dose-dependent manner. Moreover, QBMR significantly decreased weight gain and rectal temperature increase caused by ovariectomy, and the largest changes in rectal temperature were found at the lowest dose. The data suggest that QBMR's estrogenic responses show tissue variation that reflects different affinities of ERs for QBMR components. This study demonstrates that QBMR activity is mediated through estrogenic components and provides an evidence base for QBMR treatment of post-menopausal symptoms.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Estrógenos/farmacología , Glándulas Suprarrenales/patología , Animales , Peso Corporal , Medicamentos Herbarios Chinos/química , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Inmunohistoquímica , Hormona Luteinizante/sangre , Glándulas Mamarias Animales/patología , Ovariectomía , Preparaciones de Plantas , Ratas , Ratas Sprague-Dawley , Recto/patología , Temperatura , Útero/patología , Vagina/patología
9.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 34(11): 1302-5, 2014 Nov.
Artículo en Chino | MEDLINE | ID: mdl-25566618

RESUMEN

OBJECTIVE: To observe the clinical efficacy of Bushen Huoxue Sanyu Decoction (BHSD) in treatment of adenomyosis (AM) patients. METHODS: Seventy AM patients of Shen deficiency blood stasis syndrome (SDBSS) were randomly assigned to two groups, the CM treatment group (50 cases) and the Mirena group (20 cases). Patients in the CM treatment group were treated with BHSD, one dose per day. Levonorgestrel intrauterine system (Mirena) was placed in the uterine cavity of those in the Mirena group. The therapeutic course for all was 3 months. Changes of dysmenorrhea, menstrual quantity, SDBSS, CM syndrome, uterine volume, and serum CA125 levels were observed before and after treatment. RESULTS: Compared with before treatment in the same group, scores for dysmenorrhea integral, scores for menstrual quantity, scores for SDBSS, and scores for CM syndrome all decreased in the two groups after treatment (P < 0.01). Compared with before treatment in the same group, the uterine volume was reduced after treatment in the two groups (P < 0.05) and serum carbohydrate antigen CA125 levels decreased between the two groups (P < 0.05, P < 0.01). Compared with the Mirena group, scores for dysmenorrhea integral increased and scores for SDBSS decreased in the CM treatment group (P < 0.01, P < 0.05). There was no statistical difference in the uterine volume or serum carbohydrate antigen CA125 levels (P > 0.05). CONCLUSIONS: BHSD could effectively alleviate main symptoms of AM patients of QSBSS such as dysmenorrhea, profuse menstrual blood volume, and increased uterine volume, and lower scores for QSBSS and the total score for CM syndrome.


Asunto(s)
Adenomiosis/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Medicamentos Herbarios Chinos/farmacología , Dismenorrea , Femenino , Humanos , Levonorgestrel/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA